Assertio Holdings, Inc. (ASRT)
NASDAQ: ASRT · Real-Time Price · USD
0.886
+0.043 (5.09%)
At close: Dec 20, 2024, 4:00 PM
0.908
+0.022 (2.54%)
After-hours: Dec 20, 2024, 5:36 PM EST
Assertio Holdings Revenue
Assertio Holdings had revenue of $29.20M in the quarter ending September 30, 2024, a decrease of -18.03%. This brings the company's revenue in the last twelve months to $125.76M, down -25.77% year-over-year. In the year 2023, Assertio Holdings had annual revenue of $152.07M, down -2.67%.
Revenue (ttm)
$125.76M
Revenue Growth
-25.77%
P/S Ratio
0.67
Revenue / Employee
$2,372,887
Employees
53
Market Cap
84.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 152.07M | -4.17M | -2.67% |
| Dec 31, 2022 | 156.23M | 45.22M | 40.73% |
| Dec 31, 2021 | 111.01M | 2.94M | 2.72% |
| Dec 31, 2020 | 108.08M | -121.45M | -52.91% |
| Dec 31, 2019 | 229.53M | -26.54M | -10.36% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| So-Young International | 212.14M |
| 23andMe Holding Co. | 193.26M |
| Karyopharm Therapeutics | 148.44M |
| Theratechnologies | 84.32M |
| EDAP TMS | 70.72M |
| Adlai Nortye | 5.00M |
| Cibus | 4.15M |
| Entera Bio | 99.00K |
ASRT News
- 4 days ago - Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - GlobeNewsWire
- 8 days ago - Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - GlobeNewsWire
- 5 weeks ago - Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio - Business Wire
- 5 weeks ago - Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Assertio Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio - Business Wire
- 5 weeks ago - Assertio Provides Response to Letter from Short-seller - GlobeNewsWire
- 6 weeks ago - Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud - Business Wire